Sign In
Buy OPY
$99.90
+2.52 (+2.59%)
At Close: Jun 09, 2026
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:05pm, Wednesday, 05'th Feb 2025
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:01pm, Wednesday, 05'th Feb 2025
BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:05am, Wednesday, 05'th Feb 2025
FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 05'th Feb 2025
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral the
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 05'th Feb 2025
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, toda
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:30am, Wednesday, 05'th Feb 2025
PHILADELPHIA , Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, Presi
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
04:30pm, Tuesday, 04'th Feb 2025
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 04'th Feb 2025
WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,
HF Foods Group Inc. to Participate in the Oppenheimer Emerging Growth Conference
04:05pm, Tuesday, 04'th Feb 2025
LAS VEGAS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading food distributor to Asian restaurants across the United States, announc
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 04'th Feb 2025
CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 04'th Feb 2025
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, toda
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 04'th Feb 2025
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 04'th Feb 2025
BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
07:30am, Tuesday, 04'th Feb 2025
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treat
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
07:30am, Tuesday, 04'th Feb 2025
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics f
